Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSome people notice changes to their menstrual cycle while taking Mounjaro, and wonder whether those changes reverse when they stop. The short answer is that stopping tirzepatide is unlikely to cause a new menstrual disruption on its own — but the hormonal shifts that came with significant weight loss may take time to settle. Mounjaro (tirzepatide) is a prescription-only medicine, and any concerns about your cycle during or after treatment are worth discussing with your prescriber rather than managing alone. You can read more about the wider effects of tirzepatide on the body to set this in context.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
There is no established mechanism by which stopping tirzepatide directly disrupts menstruation. Mounjaro acts on GIP and GLP-1 receptors involved in appetite and blood-sugar regulation — it does not target ovarian function or sex hormones directly. So if your periods were irregular before you started, they are unlikely to become more irregular simply because you stopped the medicine.
What can shift is the hormonal environment that weight loss creates. Adipose tissue (body fat) is hormonally active: it produces and metabolises oestrogen, and significant fat loss changes that balance. Some people whose cycles had become irregular due to excess weight find they regularise on treatment; others notice temporary changes while the body adjusts to a new set point. If you stop Mounjaro and your weight gradually returns, those hormonal changes may reverse again over weeks to months. The NHS notes that weight loss can improve conditions such as polycystic ovary syndrome (PCOS), which is itself a common driver of irregular periods, you can explore how tirzepatide works for broader context. None of this is fast or predictable, and individual variation is wide.
If your period stops entirely, becomes much heavier or lighter, or changes significantly after you stop treatment, that is worth mentioning to your GP, not because Mounjaro caused it, but because any unexplained cycle change deserves proper assessment.
One practical concern that comes up frequently is the effect of tirzepatide on oral contraceptive absorption. Because Mounjaro slows gastric emptying, NHS guidance advises adding a non-oral method of contraception (such as condoms) for the first four weeks of starting treatment and for four weeks after each dose increase, the concern being that the pill may be absorbed less reliably during that adjustment period.
Stopping Mounjaro removes this concern entirely. Once tirzepatide is out of your system, gastric motility returns to its previous baseline and oral contraceptive absorption should normalise. So if you were using additional contraception as a precaution during treatment, you can discuss discontinuing that extra method with your prescriber once you have stopped tirzepatide.
The broader topic of Mounjaro and menstrual changes covers what to expect while you are actively on treatment, which is worth reading alongside this if you are weighing up when to stop.
This is a question our prescribers hear regularly. Weight loss (particularly in people with PCOS or other weight-related hormonal conditions) can restore or improve ovulation. That means fertility may increase during treatment and may remain improved (or improve further) in the period after stopping, as long as weight is maintained.
Tirzepatide is not recommended during pregnancy, breastfeeding or for anyone actively trying to conceive. The MHRA advises using contraception throughout treatment and for a washout period before attempting pregnancy. If stopping Mounjaro is specifically because you want to conceive, your prescriber will advise on appropriate timing, this is not something to decide from a general article. The clinical picture around stopping tirzepatide is worth reviewing, and our clinical team can answer questions at consultation.
One practical note: fertility returning is not always predictable or gradual. Someone who assumed they were unlikely to conceive based on previous cycles may need to revisit their contraception plans earlier than expected after weight loss on treatment.
Stopping Mounjaro is a clinical decision, not something to do because a pen ran out or a delivery was missed before the 12pm cut-off on a Friday. Weight regain is the most consistent finding after discontinuation, trials and real-world data show that without continued treatment or robust lifestyle support, much of the lost weight returns over months. The what happens after stopping Mounjaro page covers that trajectory in detail, and guidance on how to stop is available if you are planning to taper or pause.
From a menstrual-health perspective, the main message is this: stopping tirzepatide itself is not a known trigger for cycle disruption, but the hormonal consequence of weight change (in either direction) can be. Anyone with a significant underlying condition such as PCOS, endometriosis or thyroid disease should factor that into conversations with their GP before making changes to treatment. The cost of ongoing treatment is sometimes what prompts people to consider stopping; the free consultation at nume is a good place to discuss whether continuing, pausing or switching makes sense for your situation. UK clinical guidance on weight-management injections, including advice on contraception and hormone interactions, is published by NHS England, and the full prescribing detail is available in the Mounjaro SmPC on the eMC.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.